Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason T Connor

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Journal of Biopharmaceutical Statistics|January 22, 2013
Combining risk difference and risk ratio in noninferiority trials of safetyKristine R Broglio, Jason T Connor, Scott M Berry
Journal of Biopharmaceutical Statistics|April 5, 2014
Not too big, not too small: a goldilocks approach to sample size selectionKristine R Broglio, Jason T Connor, Scott M Berry
Contemporary Clinical Trials Communications|June 30, 2023
A template for the authoring of statistical analysis plansGary Stevens, Shawn Dolley, Robin Mogg, et al.
JAMA|March 24, 2015
The platform trial: an efficient strategy for evaluating multiple treatmentsScott M Berry, Jason T Connor, Roger J Lewis
Clinical Trials (London, England)|May 30, 2014
The utility of Bayesian predictive probabilities for interim monitoring of clinical trialsBenjamin R Saville, Jason T Connor, Gregory D Ayers, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|March 12, 2004
Air-charged and microtransducer urodynamic catheters in the evaluation of urethral functionJennifer T Pollak, Minda Neimark, Jason T Connor, et al.
Pharmaceutical Statistics|November 25, 2025
Simulation-Based Bayesian Predictive Probability of Success for Interim Monitoring of Clinical Trials With Competing Event Data: Two Case StudiesChiara Micoli, Alessio Crippa, Jason T Connor, et al.
Contemporary Clinical Trials|April 26, 2016
A Bayesian adaptive phase 1 design to determine the optimal dose and schedule of an adoptive T-cell therapy in a mixed patient populationMelanie Quintana, Daniel H Li, Tina M Albertson, et al.
Journal of Clinical Gastroenterology|October 20, 2004
Pneumatic dilation for the treatment of achalasia in untreated patients and patients with failed Heller myotomyJason M Guardino, Marcelo F Vela, Jason T Connor, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|May 19, 2010
Assessment of agreement between INR measures must correspond to a clinical realityKenneth M Shermock, Jason T Connor, Danielle C Lavallee, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Journal of Biopharmaceutical Statistics|January 22, 2013
Combining risk difference and risk ratio in noninferiority trials of safetyKristine R Broglio, Jason T Connor, Scott M Berry
Journal of Biopharmaceutical Statistics|April 5, 2014
Not too big, not too small: a goldilocks approach to sample size selectionKristine R Broglio, Jason T Connor, Scott M Berry
Contemporary Clinical Trials Communications|June 30, 2023
A template for the authoring of statistical analysis plansGary Stevens, Shawn Dolley, Robin Mogg, et al.
JAMA|March 24, 2015
The platform trial: an efficient strategy for evaluating multiple treatmentsScott M Berry, Jason T Connor, Roger J Lewis
Clinical Trials (London, England)|May 30, 2014
The utility of Bayesian predictive probabilities for interim monitoring of clinical trialsBenjamin R Saville, Jason T Connor, Gregory D Ayers, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|March 12, 2004
Air-charged and microtransducer urodynamic catheters in the evaluation of urethral functionJennifer T Pollak, Minda Neimark, Jason T Connor, et al.
Pharmaceutical Statistics|November 25, 2025
Simulation-Based Bayesian Predictive Probability of Success for Interim Monitoring of Clinical Trials With Competing Event Data: Two Case StudiesChiara Micoli, Alessio Crippa, Jason T Connor, et al.
Contemporary Clinical Trials|April 26, 2016
A Bayesian adaptive phase 1 design to determine the optimal dose and schedule of an adoptive T-cell therapy in a mixed patient populationMelanie Quintana, Daniel H Li, Tina M Albertson, et al.
Journal of Clinical Gastroenterology|October 20, 2004
Pneumatic dilation for the treatment of achalasia in untreated patients and patients with failed Heller myotomyJason M Guardino, Marcelo F Vela, Jason T Connor, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|May 19, 2010
Assessment of agreement between INR measures must correspond to a clinical realityKenneth M Shermock, Jason T Connor, Danielle C Lavallee, et al.
Pageof 8